5, 7, 8, 10 or 12 Panels: How to Choose the Right Drug Test for Your Needs

Walk into any conversation about workplace drug testing and it will not be long before someone raises the question of panel count. Should we use a 5-panel test? A 10-panel? Does it matter whether we go for 7 or 8? The numbers can seem arbitrary, particularly if you are new to testing, but they represent something genuinely important: which drugs you are actually screening for, and which ones you might be missing entirely.

Panel count simply refers to the number of different drug classes a single test checks for simultaneously. A 5-panel urine test screens for five substances. A 10-panel screens for ten. Each additional panel adds coverage for another drug or drug family, but also adds complexity when interpreting results, and sometimes cost. More panels is not always better – the question is whether the drugs on an extended panel are actually relevant to your situation.

In this guide I want to walk through each panel option we stock at Zoom Health, explain exactly what each one covers, and give you a clear framework for deciding which is right for your purposes – whether you are an employer building a workplace testing policy, a parent carrying out a one-off check, or an individual who wants to understand their own recent drug use.

Why Panel Count Matters More Than You Might Think

The standard 5-panel test – the format that most people think of when they imagine a workplace drug screen – was developed in the United States in the 1980s to meet federal employment testing requirements. It covers cannabis, cocaine, amphetamines, opiates, and phencyclidine (PCP). For the American workforce of that era, that coverage made reasonable sense. For UK employers in 2025, it leaves some significant gaps.

Ketamine is the most glaring omission. It is not on a standard 5-panel test. Benzodiazepines, which include prescription tranquillisers like diazepam and alprazolam that are widely misused, are often absent too. MDMA (ecstasy) is another common UK drug that a basic panel will miss. And substances like methadone and buprenorphine, which are relevant in certain industries and regions, require specific panels to detect.

The practical consequence is that an employer running a standard 5-panel programme in the UK may be creating a false sense of security. They are testing, but they are not testing for some of the drugs most commonly used by their workforce. This is not a theoretical concern – it is one of the main reasons that testing providers and occupational health professionals in the UK increasingly recommend extended panels for most workplace applications.

The 5-Panel Test: Appropriate Uses in the UK

Despite its limitations, the 5-panel format is not without value. The 5 Panel Drug Test Kit for Recruitment (£5.99) is specifically calibrated for a UK context, screening for cannabis, cocaine, amphetamines, ketamine, and opiates. This is not a traditional 5-panel in the American mould – Zoom Testing has replaced PCP (almost non-existent in the UK) with ketamine, which is a much more relevant substance for UK screening. That single substitution makes this particular product considerably more useful than a standard imported 5-panel.

A 5-panel test is the right choice when you need a fast, affordable screening tool for a clearly defined purpose – such as candidate screening in a lower-risk role – and when you are confident that the five substances covered represent the relevant risk profile for your workforce. For higher-risk industries, safety-critical roles, or any situation where you want broader assurance, a higher panel count will serve you better.

The 7-Panel Test: Adding MDMA, Benzodiazepines and Methadone

The 7 Panel Drug Test for Street Drugs (£5.99) extends coverage to include MDMA (ecstasy), benzodiazepines, and methadone alongside the core five of amphetamines, benzodiazepines, cocaine, opiates, and cannabis. At the same price point as the 5-panel recruitment kit, it represents excellent value for anyone who wants broader street drug coverage without moving to a 10-panel.

The inclusion of benzodiazepines is particularly important in a UK context. Prescription tranquillisers are frequently misused, and their sedative effects can significantly impair workplace performance and reaction times. Unlike cannabis or cocaine, benzodiazepine misuse is easily overlooked because the substances involved are legitimately prescribed – but that makes detection no less important in safety-critical settings. Similarly, MDMA is among the most commonly used recreational drugs in the UK, particularly in the 18-35 age group, yet it is absent from most standard 5-panel tests. The 7-panel addresses both of these gaps.

Methadone appears on this panel because it is relevant in certain workforce contexts, particularly in regions where opioid substitution therapy is more prevalent. A workforce with employees on methadone programmes is not unusual in some sectors, and employers should have appropriate policies in place around prescription drug use before testing for it.

The 8-Panel Test: Adding Methamphetamine Coverage

The 8 Panel Drug Test for Street Drugs (£5.99) covers the same seven substances as the 7-panel and adds methamphetamine to the list. This may seem like a minor addition, but it reflects an important shift in UK drug use patterns. Crystal meth has historically been associated primarily with North American and Australian drug markets, but its presence in the UK has grown noticeably in recent years, particularly in some urban areas and within certain communities.

For most UK employers, methamphetamine is not yet the primary concern it might be in other countries. But for organisations with a broad or geographically diverse workforce, or those in sectors where drug trends tend to emerge earlier, the 8-panel offers a useful insurance policy. It screens for everything the 7-panel covers, at the same price, with the addition of meth coverage. Results appear within three minutes, and the test is CE marked, FDA cleared, and meets SAMHSA cut-off thresholds.

The 10-Panel Test: Comprehensive UK Workplace Coverage

For most serious workplace testing applications in the UK, the 10-panel test is where I would start. The 10 Panel Drug Screen with Ketamine (£7.99) screens for amphetamines, cannabis, cocaine, benzodiazepines, buprenorphine, ketamine, methamphetamine, morphine, opiates, and methadone. That list covers virtually every substance that is likely to pose a meaningful risk in a UK workplace context, including the two most commonly missed by lower-panel tests: ketamine and buprenorphine.

Buprenorphine deserves a specific mention. It is an opioid used both as an analgesic and as a treatment for opioid dependency, and its misuse – particularly when combined with benzodiazepines – can cause serious impairment. It does not appear on a standard opiate test strip because it has a different molecular structure to the opiates those strips are calibrated for. A test that does not specifically include a buprenorphine panel will miss it entirely, even in a heavy user. The 10-panel closes that gap.

Ketamine’s inclusion is, in my view, the other critical advantage of this panel. UK survey data consistently shows that young adults are the highest-risk group for ketamine use, and yet it remains absent from most off-the-shelf drug test kits. For any employer with a younger workforce – in hospitality, retail, warehousing, delivery, or creative industries, for example – this matters. At £7.99, the 10-panel costs only £2 more than the 7 or 8-panel options and delivers considerably broader assurance.

The 12-Panel Test: Maximum Coverage Including MDMA and Specialist Substances

The 12 Panel Drug Screen with MDMA extends coverage further to include MDMA (ecstasy), barbiturates, oxycodone, and PCP, in addition to the core substances covered by the 10-panel. It is FDA approved and CLIA waived, making it suitable for professional and clinical settings as well as home use.

This is the test to reach for when you need the broadest possible screening net – for example, in healthcare settings, drug rehabilitation support contexts, or any situation where prescription drug misuse is a particular concern. Oxycodone, a powerful prescription opioid that is increasingly misused in the UK, is not detectable on standard opiate strips because its molecular structure differs from heroin and morphine. The 12-panel’s dedicated oxycodone strip is the only way to catch it without sending a sample to a laboratory. Please note that this product is subject to stock availability – check the product page for current status.

A Practical Decision Framework

Rather than thinking about this as a simple scale from fewer panels to more, it helps to think about what you are actually trying to achieve. Here is how I would approach the decision:

If you are a small employer screening new recruits in a lower-risk role, the 5 Panel Recruitment Kit (£5.99) or 7 Panel (£5.99) gives you solid coverage of the most common UK substances at minimal cost. Both are appropriate starting points for organisations without a formal drug policy framework.

If you work in a safety-critical industry – transport, construction, manufacturing, utilities, plant operation – I would recommend the 10 Panel Drug Screen with Ketamine as a minimum. The additional substances it covers, particularly ketamine and buprenorphine, are sufficiently prevalent that their absence from a testing programme represents a real gap rather than a theoretical one.

If you are a parent testing a teenager or young adult, the 10-panel is again where I would go. The drug mix most common among under-25s in the UK – cannabis, cocaine, MDMA, ketamine, benzodiazepines – maps closely onto what the 10-panel covers. You would be testing for the substances that are actually in circulation among that age group, rather than a panel designed for a different era or a different country.

If you are in a healthcare, rehabilitation, or clinical support role, the 12-panel’s inclusion of oxycodone, buprenorphine, and barbiturates may be specifically relevant. These are substances that appear in prescription contexts and whose misuse or diversion is a concern in those settings.

What All These Tests Have in Common

Across the entire multi-panel range, a few things are consistent and worth keeping in mind. All of these tests are urine-based, with detection windows of 2 to 5 days for most substances and up to 30 days for cannabis in heavy users. All return results within 3 to 5 minutes. All are CE marked and/or FDA approved, and all meet SAMHSA cut-off thresholds – the internationally recognised standard for workplace drug testing. None require specialist training or equipment beyond a clean sample container.

And critically, all of them are screening tests rather than confirmatory tests. A positive result is a strong indicator that warrants follow-up, but it should always be confirmed by laboratory GC/MS analysis before any formal action is taken – whether that is a disciplinary procedure at work or a difficult conversation at home. The multi-panel tests in this range are excellent first-line tools. They work best as part of a considered approach rather than in isolation.